PharmEnable Closes $7.5M Financing led by MP Healthcare to Develop Next Generation of Small Molecule Drugs to Treat Cancer and Neurological Diseases
22 mai 2023 04h00 HE
|
PharmEnable
$7.5M Pre-Series A financing led by new investor MP Healthcare, the venture arm of Mitsubishi Tanabe Pharma Group. Existing investors Cambridge Enterprise, University of Cambridge Enterprise Fund...
MATEON PROVIDES CORPORATE UPDATE AND ANNOUNCES THIRD QUARTER 2020 FINANCIAL RESULTS
16 nov. 2020 06h55 HE
|
Mateon Therapeutics, Inc.
AGOURA HILLS, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB: MATN) today announced financial results for the third quarter ended September...
Mateon Therapeutics Closes $2.0 Million Financing
27 juil. 2020 07h00 HE
|
Mateon Therapeutics, Inc.
AGOURA HILLS, California, July 27, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTC.QB: MATN), announced the closing of the 1st tranche of financing related to the Mateon operations and spinoff of...
Global Metabolism Drugs Market to Surpass US$ 9.9 Billion by 2026 – Coherent Market Insights
16 juil. 2018 10h00 HE
|
Coherent Market Insights
Seattle, July 16, 2018 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global metabolism drugs market was valued at US$ 5,765.3 million in 2017 and is projected to exhibit a CAGR of...